ORMP (STOCKS)
Oramed Pharmaceuticals Inc.
$3.150000
-0.100000 (-3.08%)
Prev close: $3.250000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Nadav Kidron
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $126.97M
- Employees
- 13
- P/E (TTM)
- 3.24
- P/B (TTM)
- 0.65
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$1.12 | $-0.04 | +1.1608 | +2,845.10% |
|
Jun 2025 (Q2)
|
$0.31 | $-0.04 | +0.3508 | +859.80% |
|
Mar 2025 (Q1)
|
$-0.19 | $-0.01 | -0.1798 | -1,762.75% |
|
Dec 2024 (Q4)
|
$0.00 | $-0.03 | +0.0255 | +100.00% |
Financial Statements
| Nonoperating Income/Loss | $68.09M |
| Research and Development | $5.85M |
| Operating Income/Loss | -$13.01M |
| Income/Loss From Continuing Operations After Tax | $43.81M |
| Income/Loss From Continuing Operations Before Tax | $55.74M |
| Income Tax Expense/Benefit | $11.94M |
| Net Income/Loss | $43.85M |
| Net Income/Loss Attributable To Noncontrolling Interest | $42.00K |
| Net Income/Loss Attributable To Parent | $43.81M |
| Net Income/Loss Available To Common Stockholders, Basic | $43.81M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.04 |
| Diluted Earnings Per Share | $1.00 |
| Basic Average Shares | 41,515,629 |
| Diluted Average Shares | 42,915,789 |
| Assets | $220.49M |
| Current Assets | $136.12M |
| Noncurrent Assets | $84.38M |
| Fixed Assets | $614.00K |
| Other Non-current Assets | $83.76M |
| Liabilities | $18.16M |
| Current Liabilities | $6.12M |
| Accounts Payable | $560.00K |
| Wages | $233.00K |
| Other Current Liabilities | $5.33M |
| Noncurrent Liabilities | $12.04M |
| Equity | $202.33M |
| Equity Attributable To Noncontrolling Interest | -$952.00K |
| Equity Attributable To Parent | $203.28M |
| Liabilities And Equity | $220.49M |
| Net Cash Flow From Operating Activities | -$10.59M |
| Net Cash Flow From Operating Activities, Continuing | -$10.59M |
| Net Cash Flow From Investing Activities | $22.55M |
| Net Cash Flow From Investing Activities, Continuing | $22.55M |
| Net Cash Flow From Financing Activities | -$1.93M |
| Net Cash Flow From Financing Activities, Continuing | -$1.93M |
| Exchange Gains/Losses | $41.00K |
| Net Cash Flow | $10.08M |
| Net Cash Flow, Continuing | $10.03M |
| Comprehensive Income/Loss | $43.85M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $43.85M |
| Other Comprehensive Income/Loss | $0.00 |